Top Medicare drugs headed for price cuts
By Patrick Wingrove
Aug 15 (Reuters) -The Biden administration selected 10 prescription medicines for unprecedented price negotiations by the Medicare health program for older Americans that covers 66 million people.
Below are details on the drugs, including their gross cost to Medicare between May 2022 and June 2023:
Eliquis
Blood thinner Eliquis from Bristol Myers Squibb BMY.N and Pfizer PFE.N has been one of the most expensive drugs for the Medicare health system to cover, according to the Centers for Medicare & Medicaid Services, costing it $16.5 billion for the 12 months ending June 2023.
The drug was used to treat blood clots in around 3.7 million Medicare enrollees, helping reduce the risk of stroke and similar conditions.
Jardiance
Boehringer Ingelheim and Eli Lilly's LLY.N Jardiance is used to treat type-2 diabetes, heart failure and chronic kidney disease. It cost Medicare $7 billion for 1.6 million patients in the same period, making it the second most expensive drug.
Xarelto
Eliquis rival Xarelto from Johnson & Johnson JNJ.N cost Medicare more than $6 billion between June 2022 and May 2023. The bloodthinner, which was used to treat 1.3 million enrollees, can lower the risk of stroke, deep vein thrombosis, pulmonary embolism and similar conditions.
Januvia
Merck & Co's MRK.N Januvia, used to help lower blood glucose levels in adults with type-2 diabetes, was prescribed to 869,000 patients with Medicare coverage in the year ending June 2023 at a gross cost of $4.1 billion.
Farxiga
The third diabetes drug on the government's list is Farxiga from AstraZeneca AZN.L, which is also used to treat adults with heart failure and chronic kidney disease. It cost Medicare $3.3 billion for the 12 months ending June 2023, for nearly 800,000 patients.
Entresto
Novartis' NOVN.S heart failure drug Entresto cost the Medicare agency $2.9 billion to treat almost 60,000 patients in the same period.
Enbrel
Enbrel, which is made by Amgen AMGN.O, is used to treat a range of autoimmune conditions, including rheumatoid arthritis and psoriasis. It cost Medicare $2.8 billion to treat 48,000 patients between May 2022 and June 2023.
Imbruvica
AbbVie ABBV.N and J&J's leukemia treatment Imbruvica cost the federal health plan $2.7 billion to treat 20,000 people in those 12 months.
Stelara
The blockbuster biologic Stelara from J&J, also used to treat autoimmune conditions such as Crohn's disease, came at a gross cost of $2.6 billion to Medicare in that period and was used to treat 22,000 enrollees. Biosimilar rivals of the drug are expected to launch in the U.S. from January 2025, a year before the government's negotiated prices go into effect.
NovoLog, Fiasp (insulin aspart)
Novo Nordisk's NOVOb.CO insulin aspart products, including NovoLog and Fiasp, were also included in the negotiations, having cost $2.6 billion to treat more than 750,000 people in the 12 months ending June 2023. Insulin helps manage blood glucose levels in people with type 1 and type 2 diabetes.
President Joe Biden's Inflation Reduction Act, which allowed the government to negotiate the prices of these drugs, also capped insulin out-of-pocket spending at $35 for a month's supply of each insulin product covered by Medicare.
Reporting by Patrick Wingrove; Editing by Stephen Coates
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
